Addressing Therapeutic Inertia, Basal Insulin Use in Type 2 Diabetes
b'Better glycemic control reduces complications associated with type 2 diabetes (T2D) by at least 50 percent; unfortunately, a large percentage of patients with this disease continue to exhibit poor glycemic control and subsequent increases in diabetes-related health consequences. This podcast will examine the significance of therapeutic inertia, which is the failure to initiate or intensify treatment in a timely manner using evidence-based clinical guidelines. It will also discuss different types of basal insulin, and how each can be implemented into T2D regimens.\\n \\nThis podcast is supported by an independent educational grant from Novo Nordisk, Inc.'